The LSC spans 346,000 square feet across 12 stories in a building developed by Alexandria Real Estate Equities, Inc. (ARE). The facility will be home to around 500 Lilly scientists and researchers dedicated to pushing the boundaries of delivery technology and unlocking difficult-to-treat targets in key strategic areas, including neurodegeneration, diabetes, obesity, cardiovascular diseases, and chronic pain.
Advancing RNA and DNA Research
The opening of LSC is a milestone in Lilly’s strategic vision to lead in the development of novel RNA and DNA-based medicines. The new site will enable Lilly to enhance its research capabilities, particularly in exploring new drug targets and refining delivery technologies that are critical to the company’s future therapeutic pipeline.
“The opening of LSC expands upon Lilly’s long-standing presence in the Boston area,” said Dr. Daniel Skovronsky, Chief Scientific Officer and President of Lilly Research Laboratories. “We are committed to being supportive neighbors in this hub of discovery and innovation, further collaborating with leading institutions and new talent to continue delivering transformative medicines for the people who need them most.”
Expanding Gateway Labs to the East Coast
In addition to housing Lilly’s research teams, the LSC will also host the first East Coast location of Lilly Gateway Labs, a biotech-hosting program designed to foster collaboration between Lilly and innovative biotech companies. Since its inception in San Francisco in 2019, Gateway Labs has been instrumental in supporting over 20 biotech startups, offering them access to Lilly’s resources and expertise. The Boston location will accommodate 200 people from various companies, promoting a culture of shared knowledge and real-time learning.
Lilly CEO Dave Ricks previously emphasized the importance of the Boston Seaport investment during an investor event, highlighting it as a key part of Lilly’s broader strategy to innovate in RNA and DNA therapies. “We are pushing the boundaries of delivery technology to unlock difficult-to-treat targets in key areas like neurodegeneration, diabetes, and obesity,” Ricks stated.
A Commitment to Innovation
The launch of the LSC underscores Lilly’s commitment to driving innovation in biotechnology and expanding its footprint in regions that are at the forefront of scientific discovery. As the Boston Seaport continues to emerge as a critical hub for biotech research, Lilly’s new facility is poised to play a significant role in advancing the development of life-changing therapies for patients worldwide.
https://www.prnewswire.com/news-releases/lilly-opens-state-of-the-art-research-and-development-center-in-the-boston-seaport-302219992.html
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Nanoscope Therapeutics Publishes Breakthrough Clinical Data Demonstrating Significant Vision Restoration in Retinitis Pigmentosa with Novel AAV-based MCO-010 Gene Therapy
Nanoscope Therapeutics has announced the publication of highly encouraging Phase 1/2a clinical trial data in the esteemed journal Molecular Therapy, showcasing significant vision restoration in patients suffering from retinitis pigmentosa (RP), a debilitating...
Capsida’s AAV CAP-004 Gene Therapy Shows Promise for Friedreich’s Ataxia in Primate Study at MDA Conference
Capsida Biotherapeutics' experimental gene therapy, CAP-004, for Friedreich's ataxia (FA), has demonstrated promising preclinical results in nonhuman primates. Research presented by Capsida at the 2025 MDA Clinical & Scientific Conference showed that a single...
FDA Grants Fast Track to Sanofi’s Chlamydia mRNA Vaccine
Sanofi is making significant strides in the fight against chlamydia, the most common sexually transmitted bacterial infection, for which there are currently no approved preventative vaccines. The French pharmaceutical group has recently been granted a fast-track...
Epicrispr Biotechnologies Announces $68M Series B to Advance First-in-Class FSHD Epigenetic Therapy to Clinic
Epicrispr Biotechnologies today announced the first close of its Series B financing, securing $68 million to support the clinical development of EPI-321, a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), a genetic...
Related Services
Plasmids GMP Services
AAV GMP Services
